WO2005052185A1 - Detection of no by using guanylyl cyclase and cgmp production as a readout system - Google Patents
Detection of no by using guanylyl cyclase and cgmp production as a readout system Download PDFInfo
- Publication number
- WO2005052185A1 WO2005052185A1 PCT/EP2004/013707 EP2004013707W WO2005052185A1 WO 2005052185 A1 WO2005052185 A1 WO 2005052185A1 EP 2004013707 W EP2004013707 W EP 2004013707W WO 2005052185 A1 WO2005052185 A1 WO 2005052185A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cgmp
- nos
- nitric oxide
- oxide synthase
- guanylyl cyclase
- Prior art date
Links
- 108010078321 Guanylate Cyclase Proteins 0.000 title claims abstract description 27
- 102000014469 Guanylate cyclase Human genes 0.000 title claims abstract description 27
- 238000001514 detection method Methods 0.000 title claims description 27
- 238000004519 manufacturing process Methods 0.000 title description 6
- 102000008299 Nitric Oxide Synthase Human genes 0.000 claims abstract description 81
- 108010021487 Nitric Oxide Synthase Proteins 0.000 claims abstract description 81
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims abstract description 79
- 238000000034 method Methods 0.000 claims abstract description 70
- 230000000694 effects Effects 0.000 claims abstract description 45
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 14
- 239000000758 substrate Substances 0.000 claims abstract description 13
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 13
- 239000000126 substance Substances 0.000 claims description 22
- 238000013537 high throughput screening Methods 0.000 claims description 17
- 239000004475 Arginine Substances 0.000 claims description 11
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 11
- 238000006243 chemical reaction Methods 0.000 claims description 10
- 239000003112 inhibitor Substances 0.000 claims description 10
- 239000012190 activator Substances 0.000 claims description 5
- 125000004122 cyclic group Chemical group 0.000 claims description 3
- XKMLYUALXHKNFT-UUOKFMHZSA-N Guanosine-5'-triphosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XKMLYUALXHKNFT-UUOKFMHZSA-N 0.000 claims description 2
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 claims description 2
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 1
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 abstract description 3
- 238000003556 assay Methods 0.000 description 23
- 102000004190 Enzymes Human genes 0.000 description 13
- 108090000790 Enzymes Proteins 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 235000009697 arginine Nutrition 0.000 description 10
- 239000000203 mixture Substances 0.000 description 9
- 102000007637 Soluble Guanylyl Cyclase Human genes 0.000 description 8
- 108010007205 Soluble Guanylyl Cyclase Proteins 0.000 description 8
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 7
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 7
- 102000019197 Superoxide Dismutase Human genes 0.000 description 7
- 108010012715 Superoxide dismutase Proteins 0.000 description 7
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 7
- 235000013477 citrulline Nutrition 0.000 description 7
- 229960002173 citrulline Drugs 0.000 description 7
- 229960003753 nitric oxide Drugs 0.000 description 7
- 238000003016 alphascreen Methods 0.000 description 6
- 239000012131 assay buffer Substances 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 230000004913 activation Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- VWWQXMAJTJZDQX-UHFFFAOYSA-N Flavine adenine dinucleotide Natural products C1=NC2=C(N)N=CN=C2N1C(C(O)C1O)OC1COP(O)(=O)OP(O)(=O)OCC(O)C(O)C(O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 VWWQXMAJTJZDQX-UHFFFAOYSA-N 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 description 4
- FVTCRASFADXXNN-UHFFFAOYSA-N flavin mononucleotide Natural products OP(=O)(O)OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-UHFFFAOYSA-N 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 125000001417 5'-guanylyl group Chemical group C=12N=C(N([H])[H])N([H])C(=O)C=1N=C([H])N2[C@@]1([H])[C@@](O[H])([H])[C@@](O[H])([H])[C@](C(OP(=O)(O[H])[*])([H])[H])([H])O1 0.000 description 3
- 238000002820 assay format Methods 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- BCWUDVHLRZWMBE-YJOCEBFMSA-N (Z)-diethylamino-hydroxyimino-oxidoazanium N-ethylethanamine Chemical compound CC[NH2+]CC.CCN(CC)[N+](\[O-])=N\[O-] BCWUDVHLRZWMBE-YJOCEBFMSA-N 0.000 description 2
- 102000000584 Calmodulin Human genes 0.000 description 2
- 108010041952 Calmodulin Proteins 0.000 description 2
- LHQIJBMDNUYRAM-AWFVSMACSA-N D-erythro-biopterin Chemical compound N1=C(N)NC(=O)C2=NC([C@H](O)[C@H](O)C)=CN=C21 LHQIJBMDNUYRAM-AWFVSMACSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- LHQIJBMDNUYRAM-UHFFFAOYSA-N L-erythro-Biopterin Natural products N1=C(N)NC(=O)C2=NC(C(O)C(O)C)=CN=C21 LHQIJBMDNUYRAM-UHFFFAOYSA-N 0.000 description 2
- -1 Methylenedioxy Chemical group 0.000 description 2
- 102100022397 Nitric oxide synthase, brain Human genes 0.000 description 2
- 101710111444 Nitric oxide synthase, brain Proteins 0.000 description 2
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 2
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000007877 drug screening Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- YNRCBOXEDICOIX-CLFYSBASSA-N (Z)-[bis(2-aminoethyl)amino]-hydroxyimino-oxidoazanium Chemical compound NCCN(CC[NH3+])[N+](\[O-])=N\[O-] YNRCBOXEDICOIX-CLFYSBASSA-N 0.000 description 1
- DLNIKTWGBUNSSV-LUAWRHEFSA-N (Z)-[bis(3-aminopropyl)amino]-hydroxyimino-oxidoazanium Chemical compound NCCCN([N+](\[O-])=N\[O-])CCC[NH3+] DLNIKTWGBUNSSV-LUAWRHEFSA-N 0.000 description 1
- VXGYFEOSZYEJBK-UHFFFAOYSA-N 3-(3,4-dichlorophenyl)-1-oxa-2-aza-3-azonia-4-azanidacyclopent-2-en-5-imine Chemical compound C1=C(Cl)C(Cl)=CC=C1[N+]1=NOC(=N)[N-]1 VXGYFEOSZYEJBK-UHFFFAOYSA-N 0.000 description 1
- 238000003284 AlphaScreen IgG detection kit Methods 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- NTNWOCRCBQPEKQ-YFKPBYRVSA-N N(omega)-methyl-L-arginine Chemical compound CN=C(N)NCCC[C@H](N)C(O)=O NTNWOCRCBQPEKQ-YFKPBYRVSA-N 0.000 description 1
- NTNWOCRCBQPEKQ-UHFFFAOYSA-N NG-mono-methyl-L-arginine Natural products CN=C(N)NCCCC(N)C(O)=O NTNWOCRCBQPEKQ-UHFFFAOYSA-N 0.000 description 1
- 102100028452 Nitric oxide synthase, endothelial Human genes 0.000 description 1
- 101710090055 Nitric oxide synthase, endothelial Proteins 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- ZOOGRGPOEVQQDX-UHFFFAOYSA-N cyclic GMP Natural products O1C2COP(O)(=O)OC2C(O)C1N1C=NC2=C1NC(N)=NC2=O ZOOGRGPOEVQQDX-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000012188 high-throughput screening assay Methods 0.000 description 1
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000002840 nitric oxide donor Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000029865 regulation of blood pressure Effects 0.000 description 1
- 230000010451 regulation of platelet aggregation Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
- C12Q1/32—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving dehydrogenase
Definitions
- Nitric oxide (NO) can be for example produced by nitric oxide synthase (NOS) representing a group of enzymes existing as three different isoforms of NOS: eNOS, nNOS and iNOS (Janssens, S.P. et al., 1992; Marsden, PA et al., 1992; Nakane, M.
- NOS nitric oxide synthase
- NOS activity e.g. chronic obstructive pulmonary disease (COPD), arteriosclerosis, wound-heeling ) modulation of NOS activity is wanted. Therefore, there exists a need for substances which can modulate NOS activity. Subsequently, there is a need for e.g. an ultra high throughput compatible assay which is sensitive e ⁇ ough to determine whether a substance can modulated NOS activity.
- COPD chronic obstructive pulmonary disease
- arteriosclerosis arteriosclerosis
- wound-heeling wound-heeling
- NOS activity To verify whether NOS activity indeed has been altered it is essential to measure NOS activity.
- assay systems which are not compatible to miniaturized high through put screening systems are known. Only radioactive systems for measuring arginine or citrulline are available. To make matters worse, said systems are only meaningful at high doses of arginine or citrulline and therewith respective miniaturising is not successfully possible.
- NO Since NO is only stable for a few seconds it is not regarded as a suitable read-out.
- Commercially available NO detection systems have been failed as a suitable readout technique in high throughput screening (Misko T.P. et al. 1993).
- nitric oxide was regarded as a not suitable readout since it is only stable for a few seconds.
- the present invention provides for a method for detecting NO which is surprisingly accessible to a new detection method of the present invention.
- the guanylyl cyclase is a physiological target for NO. Guanylyl cyclase becomes activated by NO several hundred fold. In the presence of GTP a said activated guanylyl cyclase catalyses the generation of cGMP. Therewith, NO causes the generation of cGMP. As disclosed in the present invention said signal transduction can be surprisingly used in an inverse direction to detect NO quantitatively.
- a high throughput compatible assay format for the detection of Nitric oxide synthase (NOS) activity employing guanylyl cyclase and cGMP as an amplification and readout system for the detection of NO.
- Our assay setup is as follows: recombinantly expressed NOS enzyme, purified NOS enzyme from a natural source or working with a cell based assay system containing NOS is used to generate NO. Adding soluble guanylyl cyclase to the system leads to an increased activation of the guanylyl cyclase enzyme. This results in the generation of cyclic GMP which is then detected using a cGMP detection system.
- a cGMP detection system e.g. commercially available detection systems can be used.
- This detection system for NO is quite sensitive since the activation of the guanylyl cyclase results in an cGMP increase.
- One activated guanylyl cyclase can generate several cGMP molecules therefore we have an amplification effect and can overcome the sensitivity issue.
- the present invention provides therewith a technical basis for a long felt need: An assay for determining whether a substance can modulate NOS activity. Therewith the invention also provides for a high throughput screening (HTS) compatible NOS activity assay for a drug screening campaign.
- HTS high throughput screening
- Nitric oxide synthase is any enzyme which is selected from a group consisting of: i-NOS (inducible NO synthase, II) e- NOS (endothelial NO synthase, III), and n-NOS (neuronal NO synthase, I)
- Nitric oxide synthase (NOS) activity is an activity which catalyzes the formation of NO by converting arginine to. citrulline with the concomitant release of NO.
- NOS activity according to the present invention includes any further conversion of any other substrate resulting in the generation of NO.
- a substrate according to the invention is every substance which can be transformed by NOS in any other substance as long as NO is produced.
- a preferred substance of the invention is arginine.
- a substance to be tested to be a modulator of NOS according to the invention is any small chemical molecule, peptide, or antibody.
- a modulator according to the invention is either an inhibitor of the invention or an activator of the invention.
- An inhibitor of the nitric oxide synthase activity according to the present invention is identifiable by an reduced level of cGMP in a method according to the invention which can be measured in the solution to which the substance to be tested (in step (c)) was added.
- An activator of the nitric oxide synthase activity according to the present invention is identifiable by an enhanced level of cGMP in a method according to the invention which can be measured in the solution to which the substance to be tested (in step (c)) was added.
- a method according to the invention is, characterized in that the method comprises:
- guanylyl cyclase and guanosin triphosphate under conditions which allow synthesis of cyclic guanosin monophosphate (cGMP);
- Measuring according to the invention is any suitable detecting method which is useful of determining cGMP quantitatively.
- a preferred method for measuring cGMP according to the invention uses an antibody which is capable of binding to cGMP.
- Said method can be used to detect NO in solution.
- Said method can additionally be used in a high throughput screening. Therefore, the present invention provides for a method for detection of nitric oxide (NO)) in an high throughput (HTS) format characterized in that the above mentioned method is performed. Said method can be performed by using a plate having at least 96 wells, more preferred is the use of a 384 well plate or a 1536 well plate. Also preferred is the use of a chip as reaction and/or readout platform.
- NO nitric oxide
- HTS high throughput
- the present invention provides for a method for measuring nitric oxide synthase activity, characterized in that the method comprises: (a) providing a solution comprising a nitric oxide synthase and a suitable substrate under conditions which allow synthesis of nitric oxide; (b) adding guanylyl cyclase and GTP under conditions which allow synthesis of cGMP; (c) measuring cGMP.
- Measuring cGMP according to the invention is any suitable detecting method which is useful of determining cGMP quantitatively.
- a preferred method for measuring cGMP according to the invention uses an antibody which is capable of binding to cGMP. Said method can be used in a high throughput screening. Therefore, the present invention provides for a method for measuring nitric oxide synthase (NOS) activity in an high throughput (HTS) format characterized in that the above mentioned method is performed. Said method can be performed by using a plate having at least 96 wells, more preferred is the use of a 384 well plate or a 1536 well plate. Also preferred is the use of a chip as reaction and/or readout platform.
- the present invention provides for a method for determining whether a substance is modulator of nitric oxide synthase activity according to the invention, characterized in that the method comprises: (a) providing a first solution comprising a nitric oxide synthase and a suitable substrate under conditions which allow synthesis of nitric oxide; (b) providing a second solution comprising a nitric oxide synthase and a suitable substrate under conditions which allow synthesis of nitric oxide; (c) adding a substance to be tested to the first or the second solution; (d) adding guanylyl cyclase and GTP under conditions which allow synthesis of cGMP to the first and the second solution; (e) measuring cGMP in the first and the second solution; (f) comparing cGMP levels of the first and the second solution, wherein a modulator of a nitric oxide synthase activity is identified by different levels of cGMP. Measuring cGMP according to the invention
- Said method can be used in a high throughput screening. Therefore the present invention provides for a method for determining whether a substance is modulator of nitric oxide synthase (NOS) activity in an high throughput (HTS) format characterized in that the above mentioned method is performed.
- Said method can be performed by using a plate having at least 96 wells, more preferred is the use of a 384 well plate or a 1536 well plate. Also preferred is the use of a chip as reaction and/or readout platform.
- all above mentioned methods of to the invention additionally comprise superoxid dismutase (SOD) which can be added together with guanylyl cyclase and GTP.
- SOD superoxid dismutase
- All methods of the present invention can be used in a high throughput screening assays.
- the present invention also provides for a kit for determining whether a substance is a modulator - i.e. an activator or an inhibitor - of NOS activity comprising: guanylyl cyclase, GTP and a system for detection of cGMP.
- Said system is any suitable detecting method which is useful of determining cGMP quantitatively.
- a preferred method for measuring cGMP according to the invention uses an antibody which is capable of binding to cGMP.
- said kit of the invention further comprises Superoxide dismutase (SOD).
- kit of the invention further comprises nitric oxid synthase (NOS) which is selected from a group consisting of: i-NOS, e-NOS, and n- NOS.
- NOS nitric oxid synthase
- This kit can additionally comprise Superoxide dismutase (SOD).
- the present invention also provides for a kit for measuring nitric oxide synthase (NOS) activity comprising: guanylyl cyclase, GTP and a system for detection of cGMP.
- Said system is any suitable detecting method which is useful of determining cGMP quantitatively.
- a preferred method for measuring cGMP according to the invention uses an antibody which is capable of binding to cGMP.
- said kit of the invention further comprises
- SOD Superoxide dismutase
- kit of the invention further comprises nitric oxid synthase (NOS) which is selected from a group consisting of: i-NOS, e-NOS, and n- NOS.
- NOS nitric oxid synthase
- This kit can additionally comprise Superoxide dismutase (SOD).
- the present invention additionally provides for a further kit for detection of nitric oxid (NO) comprising: guanylyl cyclase, GTP and a system for detection of cGMP.
- Said system is any suitable detecting method which is useful of determining cGMP quantitatively.
- a preferred method for measuring cGMP according to the invention uses an antibody which is capable of binding to cGMP.
- said kit of the invention further comprises Superoxide dismutase (SOD).
- Detection of NOS activity by using the activation of soluble guanylyl cyclase an enzyme which is well known for years (Gerzer R., et al. 1981 ; Zabel U.,et al., 1998; Hoenicka, M.et al., 1999; Lee, Y.C. et al., 2000; Kosarikov, D.N. et al.; 2001).
- NO produced by the different NOS enzymes can activate soluble guanylyl cyclase and also its membrane standing counterpart.
- a cell-lysate containing NOS as well as NOS purified from a natural source can be used (Janssens, S.P.
- non radioactive HTS compatible assay format which can be used to detect the NO produced by the NOS activity via activation of guanylyl cyclase and subsequent detection of the produced cGMP using the AlphaScreen technology in a mix and measure mode.
- Arginine as a substrate is converted by each of the three different NOS enzymes respectively, into citrulline. During this process NO is also produced. Therefore NO detection can be used to monitor directly the activity NOS enzymes. It is known that NO can directly stimulate the soluble guanylyl cyclase. This activation leads to an increase in cGMP production by the activated guanylyl cyclase. The produced cGMP can be detected and quantified. A variety of different technologies can be employed for the detection and quantification of the newly produced cGMP. This technologies can be e.g. based on HTRF (Claret E.J., et al.
- Example 2 Standard operating procedure for performing a mix and measure HTS compatible NOS activity assay.
- 3 ⁇ l of a test compound diluted in distilled water (final concentration of compounds 5 ⁇ g/ml; DMSO 1%) is mixed with 3 ⁇ l enzyme mix dissolved in assay buffer (i-NOS final 2 -10 ⁇ g/ml or e-NOS final 2-10 ⁇ g/ml or n- NOS final 2-10 ⁇ g/ml, sGC final 1 :800 000 - given amounts of respective NOS enzymes are based on total concentration of cell culture supernatant employed (insect cell recombinant expression system)).
- the assay is measured using e.g. an Alphaquest reader (Perkin Elmer), which is measuring fluorescence at 520-620 nm.
- an Alphaquest reader Perkin Elmer
- Assay buffer 25mM Tris pH 7.4, 3mM MgCI 2 , 3mM DTT, 0.05% BSA, 3 ⁇ M BH 4) 1 ⁇ M FAD, 1 ⁇ M FMN, 10 ⁇ M 4- ⁇ [3 ⁇ 4'- (Methylenedioxy) benzyl]amino ⁇ -6- methoxyquinazoline
- Stop / detection buffer 50mM Tris, 50mM EDTA pH 7.4, 0.10% BSA, 0.10% Tween-20
- Each assay microtiter plate contains wells with vehicle control instead of compound (1 % DMSO in water) as reference for non-inhibited enzyme activity (100% CTL; high values) and wells with 100 ⁇ M AMT as reference for inhibited enzyme activity (0% CTL; low values).
- Each assay micro-titer plate contains a cGMP standard curve (1 , 10, 100, 1000, 3000, 10000, 100000, 1000000 pM/l) in duplicate used as reference to calculate the amount of cGMP produced in every well.
- the 384 low volume plates were purchased from Greiner (white; cat.-no. 784075).
- the AlphaScreen IgG Detection Kit catalog.-no. 6760617) and the biotinylated cGMP were bought from Perkin Elmer.
- the anti-cGMP antibody catalog.-no. 970161 is from Merck Biosciences.
- the different NOS enzymes i-NOS (cat.-no. 201-069), e-NOS (cat.-no. 201-070) and n-NOS (cat.-no. 201-068), sGC (cat.-no.
- Example 3 Standard operating procedure for performing a mix and measure HTS compatible NOS activity assay optimized by adding a further enzyme to the reaction mixture the Superoxide dismutase (SOD)
- 3 ⁇ l of the test compounds diluted in distilled water (final concentration of compounds 5 ⁇ g/ml; DMSO 1%) is mixed with 3 ⁇ l enzyme mix dissolved in assay buffer (i-NOS final 2 ⁇ g/ml, e-NOS 5 ⁇ g/ml, n-NOs 0.4 ⁇ g/ml, SOD final 300nM, sGC final 1 :800 000 - given amounts of respective NOS enzymes are based on total concentration of cell culture supernatant employed (insect cell recombinant expression system)).
- Assay buffer 25mM Tris pH 7.4, 3mM MgCI 2 , 3mM DTT, 0.05% BSA, 3 ⁇ M BH 4 , 1 ⁇ M FAD, 1 ⁇ M FMN, 10 ⁇ M 4- ⁇ [3 ⁇ 4'- (Methylenedioxy) benzyl]amino ⁇ -6- methoxyquinazoline
- Each assay microtiter plate contains a cGMP standard curve (1 , 10, 100, 1000,
- the analysis of the data is performed by the calculation of the percentage of cGMP in the presence of the test compound compared to cGMP generated from the positive control.
- An inhibitor of the enzyme activity will give values between 100% Ctl (no inhibition) and 0% Ctl (complete inhibition).
- Example 4 Stimulation of soluble guanylyl cyclase and subseguent cGMP detection:
- the principle mechanism of the stimulation of the soluble guanylyl cyclase can be shown by using a NO donor compound like for example DEA NONOate or others like DETA NONOate, DPTA NONOate, GEA 5024 or GEA 3162 (Drago R.S. & Paulik F.E., 1960; Drago R.S. & B.R. Karstetter B.R. 1961 ; Maragos, CM. et al, 1991 ; Wink D.A., et al. 1991 ; Hrabie, et al. 1993; Robak, et al., 1992; Moilanen, E. et al. 1993; Corell, T. et al. 1994; Karup, G.
- a NO donor compound like for example DEA NONOate or others like DETA NONOate, DPTA NONOate, GEA 5024 or GEA 3162
- FIG. 1 shows the cGMP production after stimulating the soluble guanylyl cyclase with DEA NONOate in a dose dependent manner.
- an AlphaScreen competition assay was used for detection of cGMP.
- Example 5 Inhibition of different NOS enzymes using standard inhibitors:
- Table 1 summarises the results obtained by employing the assay described above and testing standard NOS inhibitors.
- AMT Nakane, M. et al., 1995; Tracey, W.R. et al., 1995; Rairigh, R.L. et al.1998;
- ODQ Boulton, C. L. et al., 1995; Brunner, F. et al.,1995; Garthwaite, J et al., 1995; Moro, M.A. et al., 1996; Schrammel, A. et al., 1996; Southam, E. et al., 1996; Abi- Gerges, N. et al., 1997; Olson, L.J, et al., 1997; Sobey C.G. & Faraci F.M. 1997; Hwang, T.L. et al., 1998; R. Motterlini, et al., 2000;
- Nitric oxide synthases structure, function and inhibition Biochem. J. (2001 ) 357, 593-615
- Marietta MA Yoon PS. lyengar R.
- Wishnok JS Macrophage oxidation of L-arginine to nitrite and nitrate: Nitric oxide is an intermediate. Biochemistry. Vol. 27(24)(pp 8706-8711 ), 1988.
- Perkin Elmer Flashplate cyclic cGMP [ 125 l]-assay product no: SMP002J001 PK Keele, B.B. Jr. et al.; Superoxide Dismutase from Escherichia coli B; JBC Vol.245, No. 22, pp6176-6181 (1970).
- Garvey, E.P et al.; 1400W is a slow, tight binding, and highly selective inhibitor of inducible nitric-oxide synthase in vitro and in vivo; J. Biol. Chem. 272, 4959 (1997)
- Figure 1 shows a Dose response testing of the synthetic NO donor DEA NONOate on the stimulation of soluble guanylyl cyclase and detection of the subsequent cGMP production of guanylyl cyclase by employing the AlphaScreen cGMP competition assay outlined in Example 4.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Abstract
A method for measuring nitric oxide synthase activity, characterized in the method comprises; (a) providing a solution comprising a nitric oxide synthase and a suitable substrate under conditions which allow synthesis of nitric oxide; (b) adding guanylyl cyclase and GTP under conditions which allow synthesis of cGMP; (c) measuring cGMP.
Description
Detection of NO by using guanylyl cyclase and cGMP production as a readout system
Introduction
The L-arginine-nitric oxide pathway is involved in a large variety of physiological processes (Mayer; B. et al., 1997; Vallance, P. et al., 2002; Wendy, K. et al., 2001), like for example the regulation of blood pressure, platelet aggregation or host defence against pathogens. Nitric oxide (NO) can be for example produced by nitric oxide synthase (NOS) representing a group of enzymes existing as three different isoforms of NOS: eNOS, nNOS and iNOS (Janssens, S.P. et al., 1992; Marsden, PA et al., 1992; Nakane, M. et al., 1993; Geller, D.A. et al., 1993; Sherman, P.A. et al. 1993; Charles, I.G. et al., 1993; Maier, R. et al., 1994; Chartrain, N.A. et al., 1994).
To influence diseases which are associated with NOS activity (e.g. chronic obstructive pulmonary disease (COPD), arteriosclerosis, wound-heeling ) modulation of NOS activity is wanted. Therefore, there exists a need for substances which can modulate NOS activity. Subsequently, there is a need for e.g. an ultra high throughput compatible assay which is sensitive eηough to determine whether a substance can modulated NOS activity.
In the following the known reaction of NOS with Arginine in presence of NADPH, FAD, FMN and biopterin resulting in Citrulline and No and NADP+ is given (Griffith, O.W. et al, 1995; Mayer, B. et al.; 1995; Stuehr, D.J. et al., 1991 ; Klatt, P. et al.,1993; Feldmann, P.L. et al, 1993; Marietta, M.A., et al., 1994; Pufahl, R.A. et al., 1993; Clement, B. et al., 1993;):
Arginine + NOS Citrulline + NO + NADP+ NADPH, FAD, FMN, biopterin
To verify whether NOS activity indeed has been altered it is essential to measure NOS activity. To measure the activity of a NOS enzyme it is necessary to detect arginine consumption, citrulline production or NO generation.
Currently, only assay systems which are not compatible to miniaturized high through put screening systems are known. Only radioactive systems for measuring arginine or citrulline are available. To make matters worse, said systems are only meaningful at high doses of arginine or citrulline and therewith respective miniaturising is not successfully possible.
Other systems are not usable for a screening campaign since a substance to be tested interacts unspecifically with substances of the system (Powell D.and Williams
D., 2002).
Since NO is only stable for a few seconds it is not regarded as a suitable read-out. Commercially available NO detection systems have been failed as a suitable readout technique in high throughput screening (Misko T.P. et al. 1993).
For a high throughput compatible NOS activity assay for a drug screening campaign it is necessary to have a sensitive and miniaturizable assay format.
Description Of The Invention
Until now nitric oxide (NO) was regarded as a not suitable readout since it is only stable for a few seconds. The present invention provides for a method for detecting NO which is surprisingly accessible to a new detection method of the present invention.
The guanylyl cyclase is a physiological target for NO. Guanylyl cyclase becomes activated by NO several hundred fold. In the presence of GTP a said activated guanylyl cyclase catalyses the generation of cGMP. Therewith, NO causes the generation of cGMP. As disclosed in the present invention said signal transduction can be surprisingly used in an inverse direction to detect NO quantitatively.
We have established a high throughput compatible assay format for the detection of Nitric oxide synthase (NOS) activity employing guanylyl cyclase and cGMP as an amplification and readout system for the detection of NO. Our assay setup is as
follows: recombinantly expressed NOS enzyme, purified NOS enzyme from a natural source or working with a cell based assay system containing NOS is used to generate NO. Adding soluble guanylyl cyclase to the system leads to an increased activation of the guanylyl cyclase enzyme. This results in the generation of cyclic GMP which is then detected using a cGMP detection system. As a cGMP detection system e.g. commercially available detection systems can be used.
This detection system for NO is quite sensitive since the activation of the guanylyl cyclase results in an cGMP increase. One activated guanylyl cyclase can generate several cGMP molecules therefore we have an amplification effect and can overcome the sensitivity issue.
The present invention provides therewith a technical basis for a long felt need: An assay for determining whether a substance can modulate NOS activity. Therewith the invention also provides for a high throughput screening (HTS) compatible NOS activity assay for a drug screening campaign.
Nitric oxide synthase (NOS) according to the present invention is any enzyme which is selected from a group consisting of: i-NOS (inducible NO synthase, II) e- NOS (endothelial NO synthase, III), and n-NOS (neuronal NO synthase, I)
Nitric oxide synthase (NOS) activity according to the present invention is an activity which catalyzes the formation of NO by converting arginine to. citrulline with the concomitant release of NO. NOS activity according to the present invention includes any further conversion of any other substrate resulting in the generation of NO.
A substrate according to the invention is every substance which can be transformed by NOS in any other substance as long as NO is produced. A preferred substance of the invention is arginine.
A substance to be tested to be a modulator of NOS according to the invention is any small chemical molecule, peptide, or antibody.
A modulator according to the invention is either an inhibitor of the invention or an activator of the invention.
An inhibitor of the nitric oxide synthase activity according to the present invention is identifiable by an reduced level of cGMP in a method according to the invention which can be measured in the solution to which the substance to be tested (in step (c)) was added.
An activator of the nitric oxide synthase activity according to the present invention is identifiable by an enhanced level of cGMP in a method according to the invention which can be measured in the solution to which the substance to be tested (in step (c)) was added.
A method according to the invention is, characterized in that the method comprises:
- providing a solution comprising NO;
- adding guanylyl cyclase and guanosin triphosphate (GTP) under conditions which allow synthesis of cyclic guanosin monophosphate (cGMP);
- measuring cGMP. Measuring according to the invention is any suitable detecting method which is useful of determining cGMP quantitatively. A preferred method for measuring cGMP according to the invention uses an antibody which is capable of binding to cGMP.
Said method can be used to detect NO in solution.
Said method can additionally be used in a high throughput screening. Therefore, the present invention provides for a method for detection of nitric oxide (NO)) in an high throughput (HTS) format characterized in that the above mentioned method is performed. Said method can be performed by using a plate having at least 96 wells, more preferred is the use of a 384 well plate or a 1536 well plate. Also preferred is the use of a chip as reaction and/or readout platform.
In one embodiment the present invention provides for a method for measuring nitric oxide synthase activity, characterized in that the method comprises:
(a) providing a solution comprising a nitric oxide synthase and a suitable substrate under conditions which allow synthesis of nitric oxide; (b) adding guanylyl cyclase and GTP under conditions which allow synthesis of cGMP; (c) measuring cGMP.
Measuring cGMP according to the invention is any suitable detecting method which is useful of determining cGMP quantitatively. A preferred method for measuring cGMP according to the invention uses an antibody which is capable of binding to cGMP. Said method can be used in a high throughput screening. Therefore, the present invention provides for a method for measuring nitric oxide synthase (NOS) activity in an high throughput (HTS) format characterized in that the above mentioned method is performed. Said method can be performed by using a plate having at least 96 wells, more preferred is the use of a 384 well plate or a 1536 well plate. Also preferred is the use of a chip as reaction and/or readout platform.
In a further embodiment the present invention provides for a method for determining whether a substance is modulator of nitric oxide synthase activity according to the invention, characterized in that the method comprises: (a) providing a first solution comprising a nitric oxide synthase and a suitable substrate under conditions which allow synthesis of nitric oxide; (b) providing a second solution comprising a nitric oxide synthase and a suitable substrate under conditions which allow synthesis of nitric oxide; (c) adding a substance to be tested to the first or the second solution; (d) adding guanylyl cyclase and GTP under conditions which allow synthesis of cGMP to the first and the second solution; (e) measuring cGMP in the first and the second solution; (f) comparing cGMP levels of the first and the second solution, wherein a modulator of a nitric oxide synthase activity is identified by different levels of cGMP. Measuring cGMP according to the invention is any suitable detecting method which is useful of determining cGMP quantitatively. A preferred method for measuring
cGMP according to the invention uses an antibody which is capable of binding to cGMP.
Said method can be used in a high throughput screening. Therefore the present invention provides for a method for determining whether a substance is modulator of nitric oxide synthase (NOS) activity in an high throughput (HTS) format characterized in that the above mentioned method is performed. Said method can be performed by using a plate having at least 96 wells, more preferred is the use of a 384 well plate or a 1536 well plate. Also preferred is the use of a chip as reaction and/or readout platform.
In a further embodiment all above mentioned methods of to the invention additionally comprise superoxid dismutase (SOD) which can be added together with guanylyl cyclase and GTP.
All methods of the present invention can be used in a high throughput screening assays.
The present invention also provides for a kit for determining whether a substance is a modulator - i.e. an activator or an inhibitor - of NOS activity comprising: guanylyl cyclase, GTP and a system for detection of cGMP. Said system is any suitable detecting method which is useful of determining cGMP quantitatively. A preferred method for measuring cGMP according to the invention uses an antibody which is capable of binding to cGMP. In a more preferred embodiment said kit of the invention further comprises Superoxide dismutase (SOD).
In a most preferred embodiment said kit of the invention further comprises nitric oxid synthase (NOS) which is selected from a group consisting of: i-NOS, e-NOS, and n- NOS. This kit can additionally comprise Superoxide dismutase (SOD).
In a further embodiment the present invention also provides for a kit for measuring nitric oxide synthase (NOS) activity comprising: guanylyl cyclase, GTP and a system for detection of cGMP. Said system is any suitable detecting method which is useful of determining cGMP quantitatively. A preferred method for measuring cGMP according to the invention uses an antibody which is capable of binding to cGMP.
In a more preferred embodiment said kit of the invention further comprises
Superoxide dismutase (SOD).
In a most preferred embodiment said kit of the invention further comprises nitric oxid synthase (NOS) which is selected from a group consisting of: i-NOS, e-NOS, and n- NOS. This kit can additionally comprise Superoxide dismutase (SOD).
The present invention additionally provides for a further kit for detection of nitric oxid (NO) comprising: guanylyl cyclase, GTP and a system for detection of cGMP. Said system is any suitable detecting method which is useful of determining cGMP quantitatively. A preferred method for measuring cGMP according to the invention uses an antibody which is capable of binding to cGMP. In a more preferred embodiment said kit of the invention further comprises Superoxide dismutase (SOD).
The following Examples are meant to illustrate the present invention, however, shall not be construed as limitation. However, the Examples describe most preferred embodiments of the invention.
Examples:
Example 1 : Assay description
Detection of NOS activity by using the activation of soluble guanylyl cyclase, an enzyme which is well known for years (Gerzer R., et al. 1981 ; Zabel U.,et al., 1998; Hoenicka, M.et al., 1999; Lee, Y.C. et al., 2000; Kosarikov, D.N. et al.; 2001). NO produced by the different NOS enzymes can activate soluble guanylyl cyclase and also its membrane standing counterpart. In said type of assays recombinantly expressed NOS, a cell-lysate containing NOS as well as NOS purified from a natural source can be used (Janssens, S.P. et al., 1992; Marsden, P.A. et al., 1992; Nakane, M. et al., 1993; Geller, D.A. et al., 1993; Sherman, P.A. et al. 1993; Charles, I.G. et al., 1993; Maier, R. et al., 1994; Chartrain, N.A. et al., 1994).
Here we describe a non radioactive HTS compatible assay format which can be used to detect the NO produced by the NOS activity via activation of guanylyl cyclase and subsequent detection of the produced cGMP using the AlphaScreen technology in a mix and measure mode.
Arginine as a substrate is converted by each of the three different NOS enzymes respectively, into citrulline. During this process NO is also produced. Therefore NO detection can be used to monitor directly the activity NOS enzymes. It is known that NO can directly stimulate the soluble guanylyl cyclase. This activation leads to an increase in cGMP production by the activated guanylyl cyclase. The produced cGMP can be detected and quantified. A variety of different technologies can be employed for the detection and quantification of the newly produced cGMP. This technologies can be e.g. based on HTRF (Claret E.J., et al. , 2004) or radioactivity (Perkin Elmer: Flashplate cyclic cGMP [125l]-assay product no: SMP002J001 PK) or like it is shown here based on the AlphaScreen technology. Using the Alphascreen cGMP competition assay a biotinylated cGMP is used to generate a fluorescence signal. The biotinylated cGMP is binding to the AlphaScreen donor bead via streptavidin and is binding to the AlphaScreen acceptor bead via an anti-cGMP specific antibody bound to the bead surface. If cGMP is freshly produced by the stimulated guanylyl cyclase it is competing with the binding to the anti-cGMP antibody. Therefore, the
standard fluorescence signal is getting reduced by freshly produced cGMP, which is not biotinylated.
Example 2: Standard operating procedure for performing a mix and measure HTS compatible NOS activity assay.
Method In 384-well plates, 3 μl of a test compound diluted in distilled water (final concentration of compounds 5 μg/ml; DMSO 1%) is mixed with 3 μl enzyme mix dissolved in assay buffer (i-NOS final 2 -10 μg/ml or e-NOS final 2-10 μg/ml or n- NOS final 2-10 μg/ml, sGC final 1 :800 000 - given amounts of respective NOS enzymes are based on total concentration of cell culture supernatant employed (insect cell recombinant expression system)). After an incubation time of 30 minutes 3μl substrate mix dissolved in assay buffer (GTP final 100μM, Arginine final 3μM, NADPH final 500μM, for n-NOS 1 μM Ca2+ and 1 μM Calmodulin is necessary) is added. After another incubation time of 90 minutes the reaction is stopped with 10 μl acceptor and donor bead-antibody mix dissolved in stop/detection buffer (final concentration of each bead-type 15 μg/ml; antibody final 1 :15000).
After an overnight incubation, the assay is measured using e.g. an Alphaquest reader (Perkin Elmer), which is measuring fluorescence at 520-620 nm.
Assay buffer: 25mM Tris pH 7.4, 3mM MgCI2, 3mM DTT, 0.05% BSA, 3μM BH4) 1 μM FAD, 1 μM FMN, 10μM 4-{[3\ 4'- (Methylenedioxy) benzyl]amino}-6- methoxyquinazoline
Stop / detection buffer: 50mM Tris, 50mM EDTA pH 7.4, 0.10% BSA, 0.10% Tween-20
Each assay microtiter plate contains wells with vehicle control instead of compound (1 % DMSO in water) as reference for non-inhibited enzyme activity (100% CTL; high values) and wells with 100μM AMT as reference for inhibited enzyme activity (0% CTL; low values).
Each assay micro-titer plate contains a cGMP standard curve (1 , 10, 100, 1000, 3000, 10000, 100000, 1000000 pM/l) in duplicate used as reference to calculate the amount of cGMP produced in every well.
5 The analysis of the data is performed by the calculation of the percentage of cGMP in the presence of the test compound compared to cGMP generated from the positive control: (cGMP(sample) - cGMP (low value)) x 100/ (cGMP (high value) - cGMP (low value)) An inhibitor of the enzyme activity will give values between 100% Ctl (no inhibition)
10 and 0% Ctl (complete inhibition).
Materials used are well known in the art, however, in the following respective 15 suppliers are given: The 384 low volume plates were purchased from Greiner (white; cat.-no. 784075).The AlphaScreen IgG Detection Kit (cat.-no. 6760617) and the biotinylated cGMP were bought from Perkin Elmer. The anti-cGMP antibody (cat.-no. 970161) is from Merck Biosciences. The different NOS enzymes i-NOS (cat.-no. 201-069), e-NOS (cat.-no. 201-070) and n-NOS (cat.-no. 201-068), sGC (cat.-no. 20 201-177) and the L-Arginine (cat.-no. 101-004) were from Alexis. The NADPH (cat.- no. N-6005) and the GTP (cat.-no. G-5884) were purchased from Sigma. All other materials were of highest grade commercially available.
Example 3: Standard operating procedure for performing a mix and measure HTS compatible NOS activity assay optimized by adding a further enzyme to the reaction mixture the Superoxide dismutase (SOD)
In the following a further variant of the assay of the invention is disclosed in which an enzyme has been added to the reaction mixture. The Superoxide dismutase (SOD) (Keele Jr. B. B. et al.,1970; Beckman J. S. et al., 1990) increases the sensitivity of the assay system and therefore reduces the amount of NOS enzyme needed for performing the assay.
Method
In the 384-well plates, 3 μl of the test compounds diluted in distilled water (final concentration of compounds 5 μg/ml; DMSO 1%) is mixed with 3 μl enzyme mix dissolved in assay buffer (i-NOS final 2μg/ml, e-NOS 5 μg/ml, n-NOs 0.4 μg/ml, SOD final 300nM, sGC final 1 :800 000 - given amounts of respective NOS enzymes are based on total concentration of cell culture supernatant employed (insect cell recombinant expression system)). After an incubation time of 30 minutes 3μl substrate mix dissolved in assay buffer ( GTP final 100μM, Arginine final 3μM, NADPH final 500μM, for nNOS 1 μM Ca2+ and 1 μM Calmodulin is necessary) is added. After another incubation time of 90 minutes the reaction is stopped with 10 μl acceptor and donor bead-antibody mix dissolved in stop/detection buffer (final concentration of each bead-type 15 μg/ml; antibody final 1 :15000). After an overnight incubation, the assay is measured using e.g. an Alphaquest (as outlined in Example 2).
Assay buffer: 25mM Tris pH 7.4, 3mM MgCI2, 3mM DTT, 0.05% BSA, 3μM BH4, 1 μM FAD, 1 μM FMN, 10μM 4-{[3\ 4'- (Methylenedioxy) benzyl]amino}-6- methoxyquinazoline
Stop / detection buffer: 50mM Tris, 50mM EDTA pH 7.4, 0.10% BSA, 0.10% Tween-20
Each assay microtiter plate contains wells with vehicle control instead of compound
(1 % DMSO in water) as reference for non-inhibited enzyme activity (100% CTL; high values) and wells with 100μM AMT as reference for inhibited enzyme activity (0%
CTL; low values). Each assay microtiter plate contains a cGMP standard curve (1 , 10, 100, 1000,
3000, 10000, 100000, 1000000 pM/l) in duplicate used as reference to calculate the amount of cGMP produced in every well.
The analysis of the data is performed by the calculation of the percentage of cGMP in the presence of the test compound compared to cGMP generated from the positive control.
(cGMP(sample) - cGMP (low value)) x 100/ (cGMP (high value) - cGMP (low value))
An inhibitor of the enzyme activity will give values between 100% Ctl (no inhibition) and 0% Ctl (complete inhibition).
Example 4: Stimulation of soluble guanylyl cyclase and subseguent cGMP detection:
The principle mechanism of the stimulation of the soluble guanylyl cyclase can be shown by using a NO donor compound like for example DEA NONOate or others like DETA NONOate, DPTA NONOate, GEA 5024 or GEA 3162 (Drago R.S. & Paulik F.E., 1960; Drago R.S. & B.R. Karstetter B.R. 1961 ; Maragos, CM. et al, 1991 ; Wink D.A., et al. 1991 ; Hrabie, et al. 1993; Robak, et al., 1992; Moilanen, E. et al. 1993; Corell, T. et al. 1994; Karup, G. et al. 1994; Malo-Ranta, U. et al. 1994; Ma H.T. et al. 1999). These type of compounds produce NO which can stimulate the soluble guanylyl cyclase which leads to a cGMP production. Figure 1 shows the cGMP production after stimulating the soluble guanylyl cyclase with DEA NONOate in a dose dependent manner. For detection of cGMP an AlphaScreen competition assay was used.
Example 5: Inhibition of different NOS enzymes using standard inhibitors:
Table 1 summarises the results obtained by employing the assay described above and testing standard NOS inhibitors.
In Table 1 is given: IC50 [μM] determination of different compounds for the different NOS enzymes.
Above mentioned NOS inhibitors are state of the art as depicted below:
AMT: Nakane, M. et al., 1995; Tracey, W.R. et al., 1995; Rairigh, R.L. et al.1998;
Briones, A-M. et al., 1999;
ODQ: Boulton, C. L. et al., 1995; Brunner, F. et al.,1995; Garthwaite, J et al., 1995; Moro, M.A. et al., 1996; Schrammel, A. et al., 1996; Southam, E. et al., 1996; Abi- Gerges, N. et al., 1997; Olson, L.J, et al., 1997; Sobey C.G. & Faraci F.M. 1997; Hwang, T.L. et al., 1998; R. Motterlini, et al., 2000;
L-NMMA: Sakuma . et al., 1988; Rees, D.D. et al., 1989;
1400W: Garvey, E.P et al., 1997; Thomsen, L.L. et al., 1997; Laszlo F. & Whittle B.J.R, 1997; Gumpricht, E. et al., 2002;
L-NI : Moore, W.M. et al., 1994.
Literature:
Meyer B. and Hemmens B. (1997) Biosynthesis and action of nitric oxide in mammalian cells Trends Biochem. Sci. 22, 477-481
Patrick Vallance and James Leiper: Blocking NO Synthesis: How, where and why ? Nature Reviews/Drug Discovery, Volume 1 December 2002, 939-950
Wendy K. Alderton, Chris E. Cooper and Richard G. Knowles: Nitric oxide synthases: structure, function and inhibition Biochem. J. (2001 ) 357, 593-615
Janssens SP. Shimouchi A. Quertermous T. Bloch DB. Bloch KD. Cloning and expression of a cDNA encoding human endothelium-derived relaxing factor/nitric oxide synthase. Journal of Biological Chemistry 267(21 ):14519-22, 1992 Jul 25.
Marsden PA. Schappert KT. Chen HS. Flowers M. Sundell CL. Wilcox JN. Lamas S. Michel T. Molecular cloning and characterization of human endothelial nitric oxide synthase. FEBS Letters. Vol. 307(3)(pp 287-293), 1992.
Nakane M. Schmidt HHHW. Pollock JS. Forstermann U. Murad F. Cloned human brain nitric oxide synthase is highly expressed in skeletal muscle. FEBS Letters. Vol. 316(2)(pp 175-180), 1993.
Geller DA. Lowenstein CJ. Shapiro RA. Nussler AK. Di Silvio M. Wang SC. Nakayama DK. Simmons RL. Snyder SH. Billiar TR. Molecular cloning and expression of inducible nitric oxide synthase from human hepatocytes. Proceedings of the National Academy of Sciences of the United States of America. Vol. 90(8)(pp 3491-3495), 1993.
Sherman PA. Laubach VE. Reep BR. Wood ER. Purification and cDNA sequence of an inducible nitric oxide synthase from a human tumor cell line. Biochemistry. Vol. 32(43)(pp 11600-11605), 1993.
Charles IG. Palmer RMJ. Hickery MS. Bayliss MT. Chubb AP. Hall VS. Moss DW. Moncada S. Cloning, characterization, and expression of a cDNA encoding an
inducible nitric oxide synthase from the human chondrocyte. Proceedings of the
National Academy of Sciences of the United States of America. Vol. 90(23)(pp
11419-1 1423), 1993.
Maier R. Bilbe G. Rediske J. Lotz M. Inducible nitric oxide synthase from human articular chondrocytes: cDNA cloning and analysis of mRNA expression. Biochimica et Biophysica Acta - Protein Structure & Molecular Enzymology. Vol. 1208(1 )(pp 145-150), 1994.
Chartrain NA. Geller DA. Koty PP. Sitrin NF. Nussler AK. Hoffman EP. Billiar TR. Hutchinson Nl. Mudgett JS. Molecular cloning, structure, and chromosomal localization of the human inducible nitric oxide synthase gene. Journal of Biological Chemistry. Vol. 269(9)(pp 6765-6772), 1994.
Griffith OW. Stuehr DJ. Nitric oxide synthases: Properties and catalytic mechanism. Annual Review of Physiology. Vol. 57(pp 707-736), 1995
Mayer, B. :Biochemistry and molecular pharmacology of nitric oxide synthases, in Nitric Oxide in the Nervous System (S.R. Vincent, ed.), Academic, New York, 21- 42,1995
Masters BSS. McMillan K. Sheta EA. Nishimura JS. Roman LJ. Martasek P. Neuronal nitric oxide synthase, a modular enzyme formed by convergent evolution: Structure studies of a cysteine thiolate-liganded heme protein that hydroxylates L-arginine to produce NO. as a cellular signal. FASEB Journal. Vol. 10(5)(pp 552-558), 1996.
Marietta MA. Yoon PS. lyengar R. Leaf CD. Wishnok JS. Macrophage oxidation of L-arginine to nitrite and nitrate: Nitric oxide is an intermediate. Biochemistry. Vol. 27(24)(pp 8706-8711 ), 1988.
Kwon NS. Nathan CF. Gilker C. Griffith OW. Matthews DE. Stuehr DJ. L-Citrulline production from L-arginine by macrophage nitric oxide synthase. The ureido
oxygen derives from dioxygen. Journal of Biological Chemistry. Vol. 265(23)(pp
13442-13445), 1990.
Mayer B. John M. Heinzel B. Werner ER. Wachter H. Schultz G. Bohme E. Brain nitric oxide synthase is a biopterin- and flavin-containing multi-functional oxido- reductase. FEBS Letters. Vol. 288(1 -2)(pp 187-191 ), 1991.
Stuehr DJ. Kwon NS. Nathan CF. Griffith OW. Feldman PL. Wiseman J. N(omega)-hydroxy-L-arginine is an intermediate in the biosynthesis of nitric oxide from L-arginine. Journal of Biological Chemistry. Vol. 266(10)(pp 6259-6263), 1991.
Klatt P. Schmidt K. Uray G. Mayer B. Multiple catalytic functions of brain nitric oxide synthase. Biochemical characterization, cofactor-requirement, and the role of N (omega )-hydroxy-L- arginine as an intermediate. Journal of Biological Chemistry. Vol. 268(20)(pp 14781-14787), 1993.
Feldmann PL. Griffith OW. And Stuehr DJ.: The surprising life of nitric oxide. Chem. Eng. News 71 , 26-38, 1993
Marietta MA. Nitric oxide synthase: Aspects concerning structure and catalysis. Cell. Vol. 78(6)(pp 927-930), 1994.
Pufahl RA. Marietta MA. Oxidation of N(G)-hydroxy-L-arginine by nitric oxide synthase: Evidence for the involvement of the heme in catalysis. Biochemical & Biophysical Research Communications. Vol. 193(3)(pp 963-970), 1993.
Clement B. Schultze-Mosgau M-H. Wohlers H. Cytochrome P450 dependent N- hydroxylation of a guanidine (debrisoquine), microsomal catalysed reduction and further oxidation of the N-hydroxy-guanidine metabolite to the urea derivative. Similarity with the oxidation of arginine to citrulline and nitric oxide. Biochemical Pharmacology. Vol. 46(12)(pp 2249-2267), 1993.
Powell D., Williams D. Nitric Oxide Synthase Screening Kit for the detection of inhibitors of NOS enzyme activity Life Science News, 2002 Amersham Biosiences
Misko T.P., Schilling R.J., Salvemini D., Moore W.M., Currie M.G. A; A Fluorometric Assay for the Measurement of Nitrate in Biological Samples Analytical Biochemistry 214, 11-16 1993
Gerzer R., et al.; Soluble guanylate cyclase purified from bovine lung contains heme and copper; FEBS Lett. 132, 71 (1981 )
Zabel U., et al.;Human soluble guanylate cyclase: functional expression and revised isoenzyme family; Biochem. J. 335 (Pt 1 ), 51 (1998)
Hoenicka, M.et al.; Purified soluble guanylyl cyclase expressed in a baculovirus/Sf9 system: stimulation by YC-1 , nitric oxide, and carbon monoxide; J. Mol. Med. 77, 14 (1999)
Lee, Y.C. et al.; Human recombinant soluble guanylyl cyclase: expression, purification, and regulation; PNAS 97, 10763 (2000)
Kosarikov, D.N. et al.; Human soluble guanylate cyclase: functional expression, purification and structural characterization; Arch. Biochem. Biophys. 388, 185 (2001 )
Claret E.J., et al. ; A new HTRF cGMP assay for monitoring Guanylyl cyclase activity; Poster presentation at the SBS Meeting in Orlando (2004)
Perkin Elmer: Flashplate cyclic cGMP [125l]-assay product no: SMP002J001 PK Keele, B.B. Jr. et al.; Superoxide Dismutase from Escherichia coli B; JBC Vol.245, No. 22, pp6176-6181 (1970).
Beckman J. S. et al. ; Apparent hydroxyl radical production by peroxynitrite: Implications for endothelial injury from nitric oxide and superoxide; Proc. Natl. Acad. Sci USA Vol 87, pp. 1620-1624 (1990).
Drago R.S. & Paulik F.E.; The Reaction of Nitrogen(ll) Oxide with Diethylamine;
JACS 82, 96 (1960)
Drago R.S. & B.R. Karstetter B.R.; The Reaction of Nitrogen(ll) Oxide with Various Primary and Secondary Amines; JACS 83, 1819 (1961 )
Maragos, CM. et al.; Complexes of NO with nucleophiles as agents for the controlled biological release of nitric oxide. Vasorelaxant effects; J. Med. Chem. 34, 3242 (1991 )
Wink D.A., et al.; DNA deaminating ability and genotoxicity of nitric oxide and its progenitors; Science 254, 1001 (1991 )
Hrabie, et al.; New nitric oxide-releasing zwitterions derived from polyamines; JOC 58, 1472 (1993)
Robak, et al.; Pharmacol. Res. 25 S2, 355 (1992)
Moilanen, E: et al.; Inhibition by nitric oxide-donors of human polymorphonuclear leucocyte functions; Br. J. Pharmacol. 109, 852 (1993)
Corell, T. et al.; Pharmacology of mesoionic oxatriazole derivatives in blood, cardiovascular and respiratory systems; Pol. J. Pharmacol. 46, 553 (1994)
Karup, G. et al.;Mesoionic oxatriazole derivatives-a new group of NO-donors; Pol. J. Pharmacol. 46, 541 (1994)
Malo-Ranta, U. et al.; Nitric oxide donor GEA 3162 inhibits endothelial cell- mediated oxidation of low density lipoprotein; FEBS Lett. 337, 179 (1994)
Ma, H.T. et al.; Ca(2+) entry activated by S-nitrosylation. Relationship to store- operated ca(2+) entry; J. Biol. Chem. 274, 35318 (1999)
Nakane, M. et al.; Novel potent and selective inhibitors of inducible nitric oxide synthase; Mol. Pharmacol. 47, 831 (1995)
Tracey, W.R. et al.; In vivo pharmacological evaluation of two novel type II (inducible) nitric oxide synthase inhibitors; Can. J. Physiol. Pharmacol. 73, 665 (1995)
Rairigh, R.L. et al.; Role of inducible nitric oxide synthase in regulation of pulmonary vascular tone in the late gestation ovine fetus; J. Clin. Invest. 101 , 15 (1998)
Briones, A-M. et al.; Role of iNOS in the vasodilator responses induced by L- arginine in the middle cerebral artery from normotensive and hypertensive rats; Br. J. Pharmacol. 126, 111 (1999)
Boulton, C. L. et al.; Nitric oxide-dependent long-term potentiation is blocked by a specific inhibitor of soluble guanylyl cyclase; Neuroscience 69, 699 (1995)
Brunner, F. et al.; Novel guanylyl cyclase inhibitor, ODQ reveals role of nitric oxide, but not of cyclic GMP in endothelin-1 secretion; FEBS Lett. 376, 262 (1995)
Garthwaite, J et al.; Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1 H-[1 ,2,4]oxadiazolo[4,3-a]quinoxalin-1-one; Mol. Pharmacol. 48, 184 (1995)
Moro, M.A. et al.; cGMP mediates the vascular and platelet actions of nitric oxide: confirmation using an inhibitor of the soluble guanylyl cyclase; PNAS 93, 1480 (1996)
Schrammel, A. et al.; Characterization of 1H-[1 ,2,4]oxadiazolo[4,3-a]quinoxalin-1- one as a heme-site inhibitor of nitric oxide-sensitive guanylyl cyclase; Mol. Pharmacol. 50, 1 (1996)
Southam, E. et al.; The nitric oxide-cyclic GMP pathway and synaptic plasticity in the rat superior cervical ganglion; Br. J. Pharmacol. 119, 527 (1996)
Abi-Gerges, N. et al. ; A comparative study of the effects of three guanylyl cyclase inhibitors on the L-type Ca2+ and muscarinic K+ currents in frog cardiac myocytes; Br. J. Pharmacol. 121 , 1369 (1997)
Olson, L.J, et al.; Selective guanylyl cyclase inhibitor reverses nitric oxide-induced vasorelaxation; Hypertension 29, 254 (1997) Sobey C.G. & Faraci F.M.; Effects of a novel inhibitor of guanylyl cyclase on dilator responses of mouse cerebral arterioles; Stroke 28, 837 (1997)
Hwang, T.L. et al.; Comparison of two soluble guanylyl cyclase inhibitors, methylene blue and ODQ, on sodium nitroprusside-induced relaxation in guinea- pig trachea; Br. J. Pharmacol 125, 1158 (1998)
Motterlini, R et al.; Endothelial heme oxygenase-1 induction by hypoxia. Modulation by inducible nitric-oxide synthase and S-nitrosothiols:; J. Biol. Chem. 275, 13613 (2000)
Sakuma.l. et al.; Identification of arginine as a precursor of endothelium-derived relaxing factor; PNAS 85, 8664 (1988)
Rees, D.D. et al.; A specific inhibitor of nitric oxide formation from L-arginine attenuates endothelium-dependent relaxation; Br. J. Pharmacol. 96, 418 (1989)
Garvey, E.P et al.; 1400W is a slow, tight binding, and highly selective inhibitor of inducible nitric-oxide synthase in vitro and in vivo; J. Biol. Chem. 272, 4959 (1997)
Thomsen, L.L. et al.; Selective inhibition of inducible nitric oxide synthase inhibits tumor growth in vivo: studies with 1400W, a novel inhibitor; Cancer Res. 57, 3300 (1997)
Laszlo F. & Whittle B.J.R.; Actions of isoform-selective and non-selective nitric oxide synthase inhibitors on endotoxin-induced vascular leakage in rat colon; Eur. J. Pharmacol. 334, 99 (1997)
Gumpricht, E. et al.; Nitric Oxide Ameliorates Hydrophobic Bile Acid-induced Apoptosis in Isolated Rat Hepatocytes by Non-mitochondrial Pathways; J. Biol. Chem. 277, 25823 (2002)
Moore, W.M. et al.; L-N6-(1-iminoethyl)Iysine: a selective inhibitor of inducible nitric oxide synthase; J. Med. Chem. 37, 3886 (1994)
Description of Figure 1 :
Figure 1 shows a Dose response testing of the synthetic NO donor DEA NONOate on the stimulation of soluble guanylyl cyclase and detection of the subsequent cGMP production of guanylyl cyclase by employing the AlphaScreen cGMP competition assay outlined in Example 4.
Claims
Claims
(1 ) A method for measuring nitric oxide synthase activity, characterized in that the method comprises: (a) providing a solution comprising a nitric oxide synthase and a suitable substrate under conditions which allow synthesis of nitric oxide; (c) adding guanylyl cyclase and GTP under conditions which allow synthesis of cGMP; (c) measuring cGMP.
2) A method according to claim 1 , 3, 4, 5, 6, 7, or 8 in which the substrate is arginine.
3) A method according to claim 1 , 2, 4, 5, 6, 7, 8, or 22 in which cGMP is measured by an antibody capable of detecting cGMP.
4) A method according to claim 1 , 2, 3, 5, 6, 7, or 8 in which the nitric oxide synthase is selected from a group consisting of: i-NOS, e-NOS, and n-NOS.
5) A method for determining whether a substance is modulator of nitric oxide synthase activity, characterized in that the method comprises: (a) providing a first solution comprising a nitric oxide synthase and a suitable substrate under conditions which allow synthesis of nitric oxide; (b) providing a second solution comprising a nitric oxide synthase and a suitable substrate under conditions which allow synthesis of nitric oxide; (c) adding a substance to be tested to the first or the second solution; (d) adding guanylyl cyclase and GTP under conditions which allow synthesis of cGMP to the first and the second solution; (e) measuring cGMP in the first and the second solution; (f) comparing cGMP levels of the first and the second solution, wherein a modulator of a nitric oxide synthase activity is identified by different levels of cGMP.
6) A method according to claim 5. in which the modulator is an inhibitor of the nitric oxide synthase activity, wherein an inhibitor is identified by an reduced level of cGMP which can be measured in the solution to which the substance in step (c) was added.
7) A method according to claim 5 in which the modulator is an activator of the nitric oxide synthase activity, wherein an activator is identified by an enhanced level of cGMP which can be measured in the solution to which the substance in step (c) was added.
8) A method according to claim 1 , 5, 6, 7, 9, 13, 17, or 22 characterised in that superoxid dismutase is added together with guanylyl cyclase and GTP.
9) A method for measuring nitric oxid synthase (NOS) activity in an high throughput (HTS) format characterized in that a method according to claim 1 , 2, 3, or 4 is performed.
10) A method according to claim 9 in which a plate having at least 96 wells is used.
11) A method according to claim 10 in which a 384 well plate or a 1536 well plate is used.
12) A method according to claim 9 in which a chip is used as reaction and/or readout platform.
13) A method for determining whether a substance is a modulator of nitric oxid synthase (NOS) activity in an high throughput (HTS) format characterized in that a method according to claim 5, 6, or 7 is performed.
14) A method according to claim 13 in which a plate having at least 96 wells is used.
15) A method according to claim 14 in which a 384 well plate or a 1536 well plate is used.
16) A method according to claim 13 in which a chip is used as reaction and/or readout platform.
5 17) A method for detecting nitric oxid (NO) in an high throughput (HTS) format characterized in that a method according to claim 22 is performed.
18) A method according to claim 17 in which a plate having at least 96 wells is used.
10 19) A method according to claim 18 in which a 384 well plate or a 1536 well plate is used.
20) A method according to claim 17 in which a chip is used as reaction and/or 15 readout platform.
21 ) Use of a method according of claim 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19, 20, or 22 in a high throughput screening.
20 22) A method for detection of nitric oxid (NO), characterized in that the method comprises: (a) providing a solution comprising NO; (b) adding guanylyl cyclase and guanosin triphosphate (GTP) under conditions which allow systhesis of cyclic guanosin monophosphate (cGMP);
25 (c) measuring cGMP.
23) A kit for determining whether a substance is a modulator of NOS activity comprising: (a) guanylyl cyclase, 30 (b) GTP, and (c) a system for detecting cGMP quantitatively.
24) A kit according to claim 23 which additionally comprises a nitric oxide synthase (NOS) which is selected from a group consisting of: i-NOS, e-NOS, and n-NOS.
25) A kit according to claim 23 or 24 comprising additionally superoxid dismutase.
26) A kit according to claim 23, 24, or 25 in which (c) is an antibody which is 5 capable of binding to cGMP.
27) A kit for measuring nitric oxid synthase (NOS) activity comprising: (a) guanylyl cyclase, (b) GTP, and
10 (c) a system for detecting cGMP quantitatively.
28) A kit according to claim 27 which additionally comprises a nitric oxide synthase (NOS) which is selected from a group consisting of: i-NOS, e-NOS, and n-NOS.
15 29) A kit according to claim 27 or 28 comprising additionally superoxid dismutase.
30) A kit according to claim 27, 28, or 29 in which (c) is an antibody which is capable of binding to cGMP.
20 31) A kit for detection of nitric oxid (NO) comprising: (a) guanylyl cyclase, (b) GTP, and (c) a system for detecting cGMP quantitatively.
25 32) A kit according to claim 31 comprising additionally superoxid dismutase.
33) A kit according to claim 31 or 32 in which (c) is an antibody which is capable of binding to cGMP.
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006540410A JP5671194B2 (en) | 2003-11-26 | 2004-11-25 | Detection of NO using guanylyl cyclase and cGMP production as a reading system |
| EP04819231A EP1689880B1 (en) | 2003-11-26 | 2004-11-25 | Detection of no by using guanylyl cyclase and cgmp production as a readout system |
| DK04819231T DK1689880T3 (en) | 2003-11-26 | 2004-11-25 | Detection of NO using guanylyl cyclase and cGMP preparation as a read-out system |
| CA2540822A CA2540822C (en) | 2003-11-26 | 2004-11-25 | Detection of no by using guanylyl cyclase and cgmp production as a readout system |
| AT04819231T ATE429508T1 (en) | 2003-11-26 | 2004-11-25 | DETECTION OF NO USING GUANYLYLCYCLASE AND CGMP PRODUCTION AS A READOUT SYSTEM |
| DE602004020795T DE602004020795D1 (en) | 2003-11-26 | 2004-11-25 | PROOF OF NO USING GUANYLYLCYCLASE AND CGMP PRODUCTION AS A READOUT SYSTEM |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03027159 | 2003-11-26 | ||
| EP03027159.7 | 2003-11-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2005052185A1 true WO2005052185A1 (en) | 2005-06-09 |
Family
ID=34626376
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2004/013707 WO2005052185A1 (en) | 2003-11-26 | 2004-11-25 | Detection of no by using guanylyl cyclase and cgmp production as a readout system |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1689880B1 (en) |
| JP (1) | JP5671194B2 (en) |
| AT (1) | ATE429508T1 (en) |
| CA (1) | CA2540822C (en) |
| DE (1) | DE602004020795D1 (en) |
| DK (1) | DK1689880T3 (en) |
| ES (1) | ES2324477T3 (en) |
| WO (1) | WO2005052185A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008019783A1 (en) * | 2006-08-18 | 2008-02-21 | Bayer Schering Pharma Aktiengesellschaft | Methods for identifying nitric oxide modulators |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5350607B2 (en) * | 2007-06-14 | 2013-11-27 | キッコーマン株式会社 | Guanylate cyclase activity assay |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002020831A2 (en) * | 2000-09-06 | 2002-03-14 | Grünenthal GmbH | Method for measurement of the activity of no-synthase |
-
2004
- 2004-11-25 ES ES04819231T patent/ES2324477T3/en active Active
- 2004-11-25 WO PCT/EP2004/013707 patent/WO2005052185A1/en not_active Application Discontinuation
- 2004-11-25 CA CA2540822A patent/CA2540822C/en active Active
- 2004-11-25 DE DE602004020795T patent/DE602004020795D1/en active Active
- 2004-11-25 DK DK04819231T patent/DK1689880T3/en active
- 2004-11-25 AT AT04819231T patent/ATE429508T1/en active
- 2004-11-25 EP EP04819231A patent/EP1689880B1/en active Active
- 2004-11-25 JP JP2006540410A patent/JP5671194B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002020831A2 (en) * | 2000-09-06 | 2002-03-14 | Grünenthal GmbH | Method for measurement of the activity of no-synthase |
Non-Patent Citations (1)
| Title |
|---|
| MAYER BERND ET AL: "A new pathway of nitric oxide/cyclic GMP signaling involving S-nitrosoglutathione", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, no. 6, 6 February 1998 (1998-02-06), pages 3264 - 3270, XP002320131, ISSN: 0021-9258 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008019783A1 (en) * | 2006-08-18 | 2008-02-21 | Bayer Schering Pharma Aktiengesellschaft | Methods for identifying nitric oxide modulators |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1689880A1 (en) | 2006-08-16 |
| EP1689880B1 (en) | 2009-04-22 |
| JP5671194B2 (en) | 2015-02-18 |
| JP2007512011A (en) | 2007-05-17 |
| ATE429508T1 (en) | 2009-05-15 |
| DK1689880T3 (en) | 2009-07-27 |
| DE602004020795D1 (en) | 2009-06-04 |
| CA2540822C (en) | 2010-09-21 |
| ES2324477T3 (en) | 2009-08-07 |
| CA2540822A1 (en) | 2005-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Schuler et al. | Functional coupling of PSST and ND1 subunits in NADH: ubiquinone oxidoreductase established by photoaffinity labeling | |
| Murphy et al. | Synthesis of nitric oxide in CNS glial cells | |
| Knowles et al. | Formation of nitric oxide from L-arginine in the central nervous system: a transduction mechanism for stimulation of the soluble guanylate cyclase. | |
| Palmer et al. | A novel citrulline-forming enzyme implicated in the formation of nitric oxide by vascular endothelial cells | |
| Iesaki et al. | Inhibition of guanylate cyclase stimulation by NO and bovine arterial relaxation to peroxynitrite and H2O2 | |
| Artz et al. | In vitro activation of soluble guanylyl cyclase and nitric oxide release: a comparison of NO donors and NO mimetics | |
| US8338125B2 (en) | Kit for measuring nitric oxide synthase activity | |
| Erdal et al. | Selective neuronal nitric oxide synthase inhibitors | |
| Edmondson et al. | Spectral and kinetic studies of imine product formation in the oxidation of p-(N, N-dimethylamino) benzylamine analogs by monoamine oxidase B | |
| Deshpande et al. | Nitric oxide modulators: an emerging class of medicinal agents | |
| Mansuy et al. | Alternative nitric oxide-producing substrates for NO synthases | |
| Mihm et al. | Effects of angiotensin II on vascular endothelial cells: formation of receptor-mediated reactive nitrogen species | |
| Silverstein et al. | Equilibrium kinetic study of the catalytic mechanism of bovine liver glutamate dehydrogenase | |
| Benedetti et al. | Effect of ageing on tissue levels of amino acids involved in the nitric oxide pathway in rat brain | |
| Tipton et al. | The catalytic behaviour of monoamine oxidase | |
| CA2540822C (en) | Detection of no by using guanylyl cyclase and cgmp production as a readout system | |
| Weaver et al. | A comparative study of neuronal and inducible nitric oxide synthases: generation of nitric oxide, superoxide, and hydrogen peroxide | |
| Wolff et al. | Inactivation of Nitric Oxide Synthase Isoforms by Diaminoguanidine andNG-Amino-L-arginine | |
| Uchiyama et al. | Functional regulation of Na+-dependent neutral amino acid transporter ASCT2 by S-nitrosothiols and nitric oxide in Caco-2 cells | |
| DOUBLET et al. | Investigations on the Kinetic Mechanism of Octopine Dehydrogenase: 1. Steady‐State Kinetics | |
| Tang et al. | Kinetic and biochemical analysis of the mechanism of action of lysine 5, 6-aminomutase | |
| Class et al. | Patent application title: Detection of NO By Using Guanylyl Cyclase and cGMP Production as a Readout System Inventors: Frank Buettner (Attenweiler, DE) Frank Buettner (Attenweiler, DE) Assignees: BOEHRINGER INGELHEIM INTERNATIONAL GMBH | |
| Suckling et al. | 6-Acetyl-7, 7-dimethyl-5, 6, 7, 8-tetrahydropterin is an activator of nitric oxide synthases | |
| JPS5935600B2 (en) | Method for quantifying transaminase and related diagnostic kit | |
| Ambekar et al. | Chloramphenicol succinate, a competitive substrate and inhibitor of succinate dehydrogenase: possible reason for its toxicity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 2540822 Country of ref document: CA |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2004819231 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2006540410 Country of ref document: JP |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
| WWP | Wipo information: published in national office |
Ref document number: 2004819231 Country of ref document: EP |